SMAD3 and neoplasm: Consistent with our previous findings [16], tumor metabolic activity in mice receiving Smad3 knockout NK cell therapy was 80% lower than mice receiving Smad3 wild-type NK cell therapy as determined by bioluminescence imaging, suggesting Smad3 significantly suppresses the anti-cancer activity of NK cells.